伏美替尼对比吉非替尼单药一线治疗表皮生长因子受体突变晚期非小细胞肺癌的成本-效果分析*
苏广全, 易仁平, 方苹苹, 夏一淼, 潘旻, 葛坤坤, 沈爱宗
Cost-effectiveness Analysis of Furmonertinib Compared to Gefitinib in First-line Monotherapy for Advanced Non-small Cell Lung Cancer with EGFR Mutation
SU Guangquan, YI Renping, FANG Pingping, XIA Yimiao, PAN Min, GE Kunkun, SHEN Aizong
医药导报
.
2024, (8): 1245
-1251
.
DOI: 10.3870/j.issn.1004-0781.2024.08.012
